Shares of Nuformix plc (LON:NFX – Get Free Report) hit a new 52-week low during trading on Wednesday . The stock traded as low as GBX 0.15 ($0.00) and last traded at GBX 0.15 ($0.00), with a volume of 2412456 shares trading hands. The stock had previously closed at GBX 0.16 ($0.00).
Nuformix Stock Performance
The stock has a fifty day simple moving average of GBX 0.18 and a 200-day simple moving average of GBX 0.20. The company has a market capitalization of £1.23 million, a P/E ratio of -1.63 and a beta of 1.20. The company has a quick ratio of 3.35, a current ratio of 1.12 and a debt-to-equity ratio of 1.17.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Featured Stories
- Five stocks we like better than Nuformix
- What is a Secondary Public Offering? What Investors Need to Know
- BHP Stock: The Under-the-Radar Growth Story in Commodities
- Investing In Preferred Stock vs. Common Stock
- Analysts Upgrade These 3 Hot Buy-and-Hold Stocks
- Health Care Stocks Explained: Why You Might Want to Invest
- Kohl’s Charts a Resilient Path in a Challenging Retail Landscape
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
